Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Oct 2021 | Liquidity and counterparty agreements | Download | |
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
07 Oct 2021 | Liquidity and counterparty agreements | Download | |
04 Oct 2021 | Liquidity and counterparty agreements | Download | |
01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Nov 2016 | Información sobre resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2016 results | Download |
08 Nov 2016 | Información sobre resultados (2) | ROVI releases the press release related to the nine-month period ended 30 September 2016 results | Download |
08 Nov 2016 | Otros sobre Gobierno Corporativo | The Company informs about the agreement of the Board of Directors with regards to the appointment of the Accounts Auditor | Download |
04 Oct 2016 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2016 | Download |
01 Aug 2016 | Acuerdos estratégicos con terceros | ROVI announces the marketing agreement of Mysimba in Spain | Download |